Updated TACTI-mel Data Presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit
March 22 2018 - 7:45PM
Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the
“Company”) is pleased to announce the presentation of updated data
from its TACTI-mel Phase I clinical trial in Australia
investigating the use of eftilagimod alpha (“efti” or “IMP321”),
the Company’s lead product candidate, in combination with
pembrolizumab (KEYTRUDA®) in unresectable or metastatic melanoma
patients.
The data has been presented in an oral presentation titled
“LAG-3: Identification & Validation of Next Generation
Checkpoint Pathway” at the Cambridge Healthtech Institute’s 3rd
Annual Immuno-Oncology Summit Europe, on 22 March 2018 at the
Hilton Canary Wharf, London.
The presentation provided updated data from the first two
cohorts of the study (since the previous data presented in November
2017 at the Society for Immunotherapy of Cancer (“SITC”) Annual
Meeting), and included the following information:
- the combination of efti (1 and 6 mg) and pembrolizumab in
advanced or metastatic melanoma patients continues to be safe and
very well tolerated;
- a durable response was observed in the patients who had a
partial or complete response; and
- a disease control rate (DCR) of 66% (8/12 patients) in patients
who all had a suboptimal response or disease progression with
pembrolizumab monotherapy.
Dr. Frédéric Triebel, Immutep’s Chief Scientific Officer and
Chief Medical Officer, commented, "The data presented at the
Immuno-Oncology Summit Europe in London continues to demonstrate
the anti-tumor activity of efti in combination with
pembrolizumab. Importantly, prior to participating in
this study, these patients were treated with pembrolizumab
monotherapy and did not achieve a meaningful therapeutic benefit
from that treatment alone.”
A copy of the presentation is available on Immutep’s website in
the Presentations section of the Investors and Media tab at:
http://www.immutep.com/investors-media/presentations.html
About the TACTI-mel clinical trial
The ongoing TACTI-mel (Two ACTive Immunotherapies in melanoma)
Phase I clinical trial is a multi-centre, open-label, dosing
escalating (1, 6 or 30 mg of efti) study evaluating the combination
of efti with pembrolizumab for 6 months, starting at treatment
cycle 5 in unresectable or metastatic melanoma patients that have
had either a suboptimal response or had disease progression with
pemobrolizumab monotherapy (clinicaltrials.gov identifier NCT
02676869). The initial study consists of three cohorts of six
patients.
Preliminary data from the first (1 mg) and second (6 mg) cohorts
were presented at the SITC 2017 Annual Meeting in November 2017. In
December 2017, it was announced that the last patient of the third
cohort (30 mg) had been dosed. Data from all three initial
cohorts is expected mid calendar year 2018.
In February 2018, Immutep expanded the TACTI-mel study by an
additional cohort of 6 patients at 30 mg of efti in combination
with pembrolizumab starting at cycle 1 and with a treatment
duration of 12 months. As announced on 22 March 2018, the
first patient from this additional cohort has received their first
dose.
About Immutep
Immutep is listed on the Australian Securities Exchange (IMM),
and on the NASDAQ (IMMP) in the U.S.
For further information please visit
www.immutep.com or contact:
U.S. Investors:Jay Campbell,
Vice President of Business Development and Investor Relations,
Immutep Limited+1 (917) 860-9404; jay.campbell@immutep.com
Australian
Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2
8234 0105; mgregorowski@citadelmagnus.com
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Jul 2023 to Jul 2024